Kangyue Xu, | |
1968 Peachtree Rd Nw, Atlanta, GA 30309-1281 | |
(404) 605-5000 | |
Not Available |
Full Name | Kangyue Xu |
---|---|
Gender | Male |
Speciality | Anesthesiology Assistant |
Experience | 9 Years |
Location | 1968 Peachtree Rd Nw, Atlanta, Georgia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1023486784 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mak Anesthesia Holdings, Llc | 4284917204 | 167 |
News Archive
Researchers have identified a potential biomarker for predicting whether a premature infant is at high risk for motor development problems, according to a study published online in the journal Radiology.
Safeguard Scientifics, Inc. (NYSE:SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it has sold an additional 2.4 million shares of its position in Clarient, Inc. (Nasdaq: CLRT) through a Clarient shelf registration on Form S-3 that was declared effective by the Securities and Exchange Commission on August 20, 2009.
Chronic inflammation after a heart attack can promote heart failure and death. University of Alabama at Birmingham researchers have now shown that activated T-cells — part of the immune system's inflammatory response — are both necessary and sufficient to produce such heart failure.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
› Verified 9 days ago
Entity Name | Piedmont Anesthesia Associates Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1407856594 PECOS PAC ID: 3577457183 Enrollment ID: O20040212000604 |
News Archive
Researchers have identified a potential biomarker for predicting whether a premature infant is at high risk for motor development problems, according to a study published online in the journal Radiology.
Safeguard Scientifics, Inc. (NYSE:SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it has sold an additional 2.4 million shares of its position in Clarient, Inc. (Nasdaq: CLRT) through a Clarient shelf registration on Form S-3 that was declared effective by the Securities and Exchange Commission on August 20, 2009.
Chronic inflammation after a heart attack can promote heart failure and death. University of Alabama at Birmingham researchers have now shown that activated T-cells — part of the immune system's inflammatory response — are both necessary and sufficient to produce such heart failure.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
› Verified 9 days ago
Entity Name | Georgia Anesthesiologists, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1740299197 PECOS PAC ID: 7315835063 Enrollment ID: O20040305000398 |
News Archive
Researchers have identified a potential biomarker for predicting whether a premature infant is at high risk for motor development problems, according to a study published online in the journal Radiology.
Safeguard Scientifics, Inc. (NYSE:SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it has sold an additional 2.4 million shares of its position in Clarient, Inc. (Nasdaq: CLRT) through a Clarient shelf registration on Form S-3 that was declared effective by the Securities and Exchange Commission on August 20, 2009.
Chronic inflammation after a heart attack can promote heart failure and death. University of Alabama at Birmingham researchers have now shown that activated T-cells — part of the immune system's inflammatory response — are both necessary and sufficient to produce such heart failure.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
› Verified 9 days ago
Entity Name | Wellstar Medical Group, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
Researchers have identified a potential biomarker for predicting whether a premature infant is at high risk for motor development problems, according to a study published online in the journal Radiology.
Safeguard Scientifics, Inc. (NYSE:SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it has sold an additional 2.4 million shares of its position in Clarient, Inc. (Nasdaq: CLRT) through a Clarient shelf registration on Form S-3 that was declared effective by the Securities and Exchange Commission on August 20, 2009.
Chronic inflammation after a heart attack can promote heart failure and death. University of Alabama at Birmingham researchers have now shown that activated T-cells — part of the immune system's inflammatory response — are both necessary and sufficient to produce such heart failure.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
› Verified 9 days ago
Entity Name | Mak Anesthesia Holdings, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1912452939 PECOS PAC ID: 4284917204 Enrollment ID: O20170216001563 |
News Archive
Researchers have identified a potential biomarker for predicting whether a premature infant is at high risk for motor development problems, according to a study published online in the journal Radiology.
Safeguard Scientifics, Inc. (NYSE:SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it has sold an additional 2.4 million shares of its position in Clarient, Inc. (Nasdaq: CLRT) through a Clarient shelf registration on Form S-3 that was declared effective by the Securities and Exchange Commission on August 20, 2009.
Chronic inflammation after a heart attack can promote heart failure and death. University of Alabama at Birmingham researchers have now shown that activated T-cells — part of the immune system's inflammatory response — are both necessary and sufficient to produce such heart failure.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Kangyue Xu, 3670 Village Springs Dr, High Point, NC 27265-9454 Ph: (336) 314-4335 | Kangyue Xu, 1968 Peachtree Rd Nw, Atlanta, GA 30309-1281 Ph: (404) 605-5000 |
News Archive
Researchers have identified a potential biomarker for predicting whether a premature infant is at high risk for motor development problems, according to a study published online in the journal Radiology.
Safeguard Scientifics, Inc. (NYSE:SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it has sold an additional 2.4 million shares of its position in Clarient, Inc. (Nasdaq: CLRT) through a Clarient shelf registration on Form S-3 that was declared effective by the Securities and Exchange Commission on August 20, 2009.
Chronic inflammation after a heart attack can promote heart failure and death. University of Alabama at Birmingham researchers have now shown that activated T-cells — part of the immune system's inflammatory response — are both necessary and sufficient to produce such heart failure.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
› Verified 9 days ago
Matthew Lewis, PAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1405 Clifton Rd Ne Fl 3, Atlanta, GA 30322 Phone: 404-785-6670 Fax: 404-785-1362 | |
Elizabeth Ikeda, Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1365 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-778-8311 | |
Amar R Herndon, Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1000 Johnson Ferry Rd Ne, Atlanta, GA 30342 Phone: 770-645-9181 | |
Shelley S Staton, PAAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1000 Johnson Ferry Rd, Atlanta, GA 30342 Phone: 770-645-9181 Fax: 770-645-8455 | |
Mr. Grant Michael Mury, PAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 550 Peachtree St Ne, Atlanta, GA 30308 Phone: 404-778-3900 | |
Ashley Schade, PAAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 5665 Peachtree Dunwoody Rd, Atlanta, GA 30342 Phone: 706-543-3449 | |
Jiaqi Tracy Li, PAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1001 Johnson Fy Rd Ne, Atlanta, GA 30342 Phone: 404-785-2008 Fax: 404-785-4496 |